Figure 3From: Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysisClinical outcomes of KIT mutation-positive subgroup versus KIT mutation-negative subgroup. (a) Recurrence; (b) metastasis; and (c) 3-year overall survival.Back to article page